Clinical and economic benefits of fidaxomicin compared to vancomycin for Clostridium difficile infection

Antimicrobial Agents and Chemotherapy
Jason C GallagherManish Trivedi

Abstract

We studied the clinical and economic impact of a protocol encouraging the use of fidaxomicin as a first-line drug for treatment of Clostridium difficile infection (CDI) in patients hospitalized during a 2-year period. This study evaluated patients who received oral vancomycin or fidaxomicin for the treatment of CDI during a 2-year period. All included patients were eligible for administration of fidaxomicin via a protocol that encouraged its use for selected patients. The primary clinical endpoint was 90-day readmission with a diagnosis of CDI. Hospital charges and insurance reimbursements for readmissions were calculated along with the cost of CDI therapy to estimate the financial impact of the choice of therapy. Recurrences were seen in 10/49 (20.4%) fidaxomicin patients and 19/46 (41.3%) vancomycin patients (P = 0.027). In a multivariate analysis that included determinations of severity of CDI, serum creatinine increases, and concomitant antibiotic use, only fidaxomicin was significantly associated with decreased recurrence (adjusted odds ratio [aOR], 0.33; 95% confidence interval [CI], 0.12 to 0.93). The total lengths of stay of readmitted patients were 183 days for vancomycin and 87 days for fidaxomicin, with costs of $454...Continue Reading

References

Jul 24, 2002·The American Journal of Gastroenterology·Lynne V McFarlandChristina M Surawicz
Oct 31, 2008·The New England Journal of Medicine·Ciarán P Kelly, J Thomas LaMont
Mar 24, 2010·Infection Control and Hospital Epidemiology : the Official Journal of the Society of Hospital Epidemiologists of America·Stuart H CohenUNKNOWN Infectious Diseases Society of America
Feb 4, 2011·The New England Journal of Medicine·Thomas J LouieUNKNOWN OPT-80-003 Clinical Study Group
Sep 22, 2012·American Journal of Health-system Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists·Cheryl A Thompson
Feb 27, 2013·The American Journal of Gastroenterology·Christina M SurawiczBrian S Zuckerbraun
May 7, 2014·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Stuart JohnsonUNKNOWN Polymer Alternative for CDI Treatment (PACT) investigators
Jan 15, 2015·Infectious Disease Clinics of North America·Dale N Gerding, Fernanda C Lessa
Feb 26, 2015·The New England Journal of Medicine·Fernanda C LessaL Clifford McDonald

❮ Previous
Next ❯

Citations

Aug 19, 2016·SpringerPlus·Dhara N ShahKevin W Garey
Nov 20, 2016·Pharmacotherapy·Teena ChopraSherwood L Gorbach
Mar 14, 2017·Expert Opinion on Investigational Drugs·Bradley T EndresKevin W Garey
Feb 27, 2016·F1000Research·Meera B AvilaAndrew W Dupont
Mar 25, 2017·American Journal of Health-system Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists·Velliyur VisweshMichael A Nowak
Sep 30, 2017·APMIS : Acta Pathologica, Microbiologica, Et Immunologica Scandinavica·Pavel CermakPavel Bostik
Sep 19, 2019·Future Microbiology·Richard J VickersMark H Wilcox
Dec 24, 2016·Journal of Clinical Gastroenterology·Clayton M SpicelandDarrell S Pardi
Apr 15, 2020·The Journal of Antimicrobial Chemotherapy·Beverly MurrayDean Shinabarger
Jun 24, 2017·Open Forum Infectious Diseases·Kristen L BunnellStuart Johnson
Nov 15, 2020·International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases·Sylvia PolivkovaJiri Benes
Mar 14, 2020·Journal of Infection and Chemotherapy : Official Journal of the Japan Society of Chemotherapy·Hiroyuki OkumuraMarci English
Apr 21, 2021·Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases·Jiahe ChenJoel W Hay

❮ Previous
Next ❯

Related Concepts

Related Feeds

Aminoglycosides (ASM)

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

CRISPR Screens in Drug Resistance

CRISPR-Cas system enables the editing of genes to create or correct mutations. This feed focuses on the application of CRISPR-Cas system in high-throughput genome-wide screens to identify genes that may confer drug resistance.

Aminoglycosides

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Related Papers

Journal of Gastroenterology and Hepatology
Michael J LippMark A Callahan
The Canadian Journal of Infectious Diseases & Medical Microbiology = Journal Canadien Des Maladies Infectieuses Et De La Microbiologie Médicale
Monika WagnerMireille Goetghebeur
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
Sarah M BartschBruce Y Lee
© 2021 Meta ULC. All rights reserved